| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5689242 | European Urology | 2017 | 9 Pages |
Abstract
Cisplatin-resistant bladder cancer overexpresses particular sugar chains compared with chemotherapy-naïve bladder cancer. Using a recombinant protein from the malaria parasite Plasmodium falciparum, we can target these sugar chains, and our results showed a significant antitumor effect in cisplatin-resistant bladder cancer. This novel treatment paradigm provides therapeutic access to bladder cancers not responding to cisplatin.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Roland Seiler, Htoo Zarni Oo, Davide Tortora, Thomas M. Clausen, Chris K. Wang, Gunjan Kumar, Marina Ayres Pereira, Maj S. Ãrum-Madsen, Mette Ã. Agerbæk, Tobias Gustavsson, Mie A. Nordmaj, Jamie R. Rich, Nada Lallous, Ladan Fazli, Sherry S. Lee,